Schulman Associates Institutional Review Board, Inc. announced the acquisition of Florida-based Independent Investigational Review Board, Inc. The transaction allows both organizations, which protect the rights of human research subjects, to provide a more comprehensive suite of review services for pharmaceutical, medical device, Contract Research Organization (CRO) and clinical research site customers.
"The strengths of the two organizations are remarkably complimentary," said Michael Woods, President and CEO of Schulman. "We are very excited by the added resources and capabilities Independent brings to the combined company."
With offices in Cincinnati, Ohio, and Plantation, Fl., the combined organization will aim to provide the highest level of quality research review services for a very broad range of therapeutic areas and types of human subject research. Separately, each organization is accredited by Association for the Accreditation of Human Research Protection Programs (AAHRPP), and each has a clean recent audit history with Food and Drug Administration. Both organizations, in business more than 20 years, also enjoy strong reputations for performing thoughtful and rigorous reviews while providing the highest level of customer service available.
"Joining with Schulman allows Independent to provide the advantages of enhanced WebPortal and IT features to our established customer base," said Kim Lerner, outgoing CEO of Independent.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.